🔎 Trials Near Me

Utama › Poliradikuloneuropati Demielinasi Inflamatori Kronik › Missouri

Kajian klinikal Poliradikuloneuropati Demielinasi Inflamatori Kronik di Missouri

5 kajian untuk Poliradikuloneuropati Demielinasi Inflamatori Kronik sedang mencari peserta di lokasi di Missouri.

Bandar di Missouri

Teks kajian rasmi (Bahasa Inggeris)

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  • Kansas City Veterans Affairs Medical Center, Kansas City
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05327114

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  • Washington University School of Medicine - Siteman Cancer Center- Site Number : 8400037, St Louis
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06290141

A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

  • The Curators of the University of Missouri on behalf of University of Missouri Health Care, Columbia
  • The Washington University, St Louis
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Apr 2026 · NCT06798012

Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease

  • NextGen Precision Health Building, Clinical and Translational Science Unit, Columbia
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Mac 2026 · NCT07478172

A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

  • The Washington University, St Louis
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Jan 2026 · NCT06747351

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.